HPC8
MCID: PRS130
MIFTS: 32

Prostate Cancer, Hereditary, 8 (HPC8)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 8

MalaCards integrated aliases for Prostate Cancer, Hereditary, 8:

Name: Prostate Cancer, Hereditary, 8 57
Predisposing for Prostate Cancer 57 13
Predisposing for Prostate Cancer; Pcap 57
Prostate Cancer, Susceptibility to 57
Prostate Cancer 57
Hpc8 57
Pcap 57

Classifications:



External Ids:

OMIM® 57 602759
MedGen 41 C1864472

Summaries for Prostate Cancer, Hereditary, 8

MalaCards based summary : Prostate Cancer, Hereditary, 8, also known as predisposing for prostate cancer, is related to prostate cancer and prostate cancer, hereditary, 1. An important gene associated with Prostate Cancer, Hereditary, 8 is PCAP (Predisposing For Prostate Cancer). The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node.

More information from OMIM: 602759

Related Diseases for Prostate Cancer, Hereditary, 8

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1216)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 12.3
2 prostate cancer, hereditary, 1 11.7
3 prostate cancer, hereditary, 2 11.7
4 prostate cancer, hereditary, 13 11.6
5 prostate cancer, hereditary, 12 11.6
6 prostate cancer, hereditary, 4 11.6
7 prostate cancer, hereditary, 11 11.6
8 pachyonychia congenita 3 11.5
9 prostate cancer, hereditary, 3 11.5
10 prostate cancer, hereditary, 6 11.4
11 prostate cancer, hereditary, 9 11.4
12 prostate cancer, hereditary, x-linked 1 11.4
13 prostate cancer/brain cancer susceptibility 11.4
14 prostatic hypertrophy 11.4
15 prostate cancer, hereditary, 7 11.4
16 prostatic hyperplasia, benign 11.4
17 prostatic adenoma 11.4
18 prostate cancer, hereditary, 10 11.3
19 prostate cancer, hereditary, 15 11.3
20 prostate cancer, hereditary, 14 11.3
21 prostate disease 11.3
22 prostate cancer, hereditary, x-linked 2 11.3
23 prostate cancer, hereditary, 5 11.3
24 suppression of tumorigenicity 12 11.2
25 impotence 11.2
26 diethylstilbestrol syndrome 11.1
27 radiation proctitis 11.1
28 hereditary breast ovarian cancer syndrome 11.1
29 prostate cancer aggressiveness quantitative trait locus on chromosome 19 11.1
30 breast-ovarian cancer, familial 2 11.1
31 alopecia, androgenetic, 1 11.1
32 breast-ovarian cancer, familial 1 11.0
33 prostate sarcoma 11.0
34 gastric cancer, hereditary diffuse 11.0
35 severe combined immunodeficiency 11.0
36 prostatitis 11.0
37 sexual disorder 10.9
38 neutropenia 10.9
39 adenocarcinoma 10.9
40 hypoxia 10.9
41 bladder cancer 10.9
42 bone disease 10.9
43 body mass index quantitative trait locus 1 10.9
44 proctitis 10.8
45 bone resorption disease 10.8
46 insulin-like growth factor i 10.8
47 hypogonadism 10.8
48 47,xyy 10.8
49 pik3ca-related overgrowth syndrome 10.8
50 bone mineral density quantitative trait locus 8 10.8

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 8:



Diseases related to Prostate Cancer, Hereditary, 8

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 8

Clinical features from OMIM®:

602759 (Updated 05-Apr-2021)

Drugs & Therapeutics for Prostate Cancer, Hereditary, 8

Drugs for Prostate Cancer, Hereditary, 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 762)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 4 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
3
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
4
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
7
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
14
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
15
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
16
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
17
Ondansetron Approved Phase 4 99614-02-5 4595
18
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
19
Desflurane Approved Phase 4 57041-67-5 42113
20
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
21
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
22
Zoledronic Acid Approved Phase 4 118072-93-8 68740
23
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
24
Denosumab Approved Phase 4 615258-40-7
25
Pamidronate Approved Phase 4 40391-99-9 4674
26
Abarelix Approved, Investigational, Withdrawn Phase 4 183552-38-7 16131215
27
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
29
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
30 Analgesics, Opioid Phase 4
31 Analgesics Phase 4
32 calcium channel blockers Phase 4
33 Dong Quai Phase 4
34 Angelica Phase 4
35 Plasma Substitutes Phase 4
36 Blood Substitutes Phase 4
37 Anesthetics, Local Phase 4
38 Neurotransmitter Agents Phase 4
39 Psychotropic Drugs Phase 4
40 Excitatory Amino Acid Antagonists Phase 4
41 Anti-Anxiety Agents Phase 4
42 Hypnotics and Sedatives Phase 4
43 Anesthetics, Intravenous Phase 4
44 Anti-Ulcer Agents Phase 4
45 Antacids Phase 4
46 GABA Modulators Phase 4
47 Adrenergic alpha-Agonists Phase 4
48 Adrenergic Agonists Phase 4
49 Hydroxyethyl Starch Derivatives Phase 4
50 Ophthalmic Solutions Phase 4

Interventional clinical trials:

(show top 50) (show all 4373)
# Name Status NCT ID Phase Drugs
1 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
2 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
3 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
4 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
5 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
6 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
7 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
8 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
9 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
10 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
11 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
12 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
13 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
14 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
15 Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
16 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
17 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
18 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
19 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
20 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
21 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
22 A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) Completed NCT03035032 Phase 4 Leuprolide
23 Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy Completed NCT01083199 Phase 4
24 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
25 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
26 The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
27 The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients Completed NCT04776889 Phase 4 Rosuvastatin 20mg
28 Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study Completed NCT02773251 Phase 4 hyaluronic acid-carboxymethylcellulose
29 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
30 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
31 A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients Completed NCT01753297 Phase 4 Triptorelin 11.25 mg
32 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
33 A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
34 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
35 A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) Completed NCT02485691 Phase 4 cabazitaxel XRP6258;enzalutamide;abiraterone acetate;prednisone
36 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
37 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption & Anxiety & Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill
38 Effect of Hydroxyethyl Starch on Renal Handling of Sodium and Water, Vasoactive Hormones,Biomarkers and the Circulatory System in Patients Undergoing Radical Prostatectomy Completed NCT01486563 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9 mg/ml
39 A Prospective Study to Evaluate the Effect of Preoperative Topical Brimonidine Tartrate 0.2% (Allergan, Irvine, CA) on Intraocular Pressure (IOP) of Patients Undergoing Robot-assisted Laparoscopic Prostatectomy (RALP) Completed NCT02818816 Phase 4 brimonidine tartrate 0.2%
40 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
41 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
42 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
43 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
44 Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
45 Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
46 The Use of Thermal Suits as Preventing Hypothermia During Surgery Completed NCT01571544 Phase 4
47 A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure Completed NCT01977651 Phase 4 Enzalutamide
48 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide in Patients Undergoing Laparoscopic Surgery Completed NCT02149628 Phase 4 propofol;Desflurane
49 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
50 Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test Completed NCT01296672 Phase 4 Finasteride;Placebo

Search NIH Clinical Center for Prostate Cancer, Hereditary, 8

Genetic Tests for Prostate Cancer, Hereditary, 8

Anatomical Context for Prostate Cancer, Hereditary, 8

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 8:

40
Prostate, Bone, Lymph Node, T Cells, Bone Marrow, Breast, Colon

Publications for Prostate Cancer, Hereditary, 8

Articles related to Prostate Cancer, Hereditary, 8:

# Title Authors PMID Year
1
PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. 57
11313747 2001
2
Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. 57
10090894 1999
3
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. 57
9585607 1998
4
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. 57
8910276 1996
5
[Hereditary prostate cancer]. 61
15510898 2004
6
Heterogeneity in genetic susceptibility to prostate cancer. 61
11173005 2001

Variations for Prostate Cancer, Hereditary, 8

Expression for Prostate Cancer, Hereditary, 8

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 8.

Pathways for Prostate Cancer, Hereditary, 8

GO Terms for Prostate Cancer, Hereditary, 8

Sources for Prostate Cancer, Hereditary, 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....